1. Home
  2. MOBX vs IFRX Comparison

MOBX vs IFRX Comparison

Compare MOBX & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobix Labs Inc.

MOBX

Mobix Labs Inc.

N/A

Current Price

$0.88

Market Cap

17.6M

Sector

N/A

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$0.95

Market Cap

60.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MOBX
IFRX
Founded
2020
2007
Country
United States
Germany
Employees
46
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.6M
60.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
MOBX
IFRX
Price
$0.88
$0.95
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
98.7M
188.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$0.71
52 Week High
$1.44
$1.94

Technical Indicators

Market Signals
Indicator
MOBX
IFRX
Relative Strength Index (RSI) 65.73 54.07
Support Level $0.78 $0.81
Resistance Level $0.92 $1.16
Average True Range (ATR) 0.17 0.06
MACD 0.09 0.01
Stochastic Oscillator 61.39 71.55

Price Performance

Historical Comparison
MOBX
IFRX

About MOBX Mobix Labs Inc.

Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: